Many State Medicaid Programs Still Require Prior Authorization for Buprenorphine Treatment for Opioid Use Disorder
Removing Barriers Could Improve Patient Outcomes
Opioid Epidemic
In Their Own Words
Fentanyl Remains the Big Driver of Overdoses so Stay Focused on Naloxone as an Antidote
LDI’s Jeanmarie Perrone Names Biggest Takeaways from NIDA’s Conference on Opioid Care
Print:
Federal officials and caregivers have been in a race to combat a surge in overdoses from the combination of the opioid fentanyl and the animal sedative xylazine. The Biden Administration declared the combination an “emerging threat” in April 2023, marking the first time that designation has ever been used. It was given for the sharp rise in overdoses and skin wounds that the combination was causing across the nation.
In June a large group of experts met under the auspices of the National Institute on Drug Abuse to review testing, treatment and wound care for this combination, also called Tranq Dope. Then in July came the release of a National Response Plan.
LDI Senior Fellow Jeanmarie Perrone, a leading addiction expert at the University of Pennsylvania, was co-chair of the NIDA meeting. Here are some highlights she culled from the event.
- Continue to make naloxone widely available and encourage its use in suspected overdoses. Despite the rise of xylazine-fentanyl overdoses, naloxone remains the mainstay of overdose care because it reverses the effects of fentanyl, which is the primary reason that people stop breathing.
- Demystify the use of methadone in hospital settings. All patients with drug-induced withdrawal should be treated quickly with a patient-centered, approach. Most patients using xylazine-fentanyl have severe opioid dependence requiring withdrawal treatment with full opioid agonists such as methadone.
- The wounds from xylazine should be managed with more frequent wound care access. We need more low-barrier, walk-in wound care co-located with syringe services and other harm reduction and treatment services.
- Expand testing with rapid turnarounds. This will help manage wounds, withdrawal and overdoses and better track the spread of xylazine-fentanyl across regions to inform local interventions. We have no rapid testing for xylazine.
- Bring the focus back to fentanyl. Xylazine-fentanyl overdoses are concerning, but patients who overdose on xylazine-fentanyl have lower fatality rates compared to fentanyl alone. Fentanyl (and other potent opioids such as nitazines) are driving opioid overdoses.
Author
Jeanmarie Perrone, MD
Professor, Emergency Medicine, Perelman School of Medicine; Director, Penn Center for Addiction Medicine and Policy, Perelman School of Medicine
More on Opioid Epidemic
LDI Experts Analyze the New U.S. Plan to Target Xylazine-Laced Fentanyl
Some Doubt That It Goes Far Enough
Feds Severely Restricted Methadone Doses at Home for Opioid Addiction for Years
What Happened When SAMSHA, an Agency of the Federal Government, Relaxed This Restriction Because of COVID-19?
Dear Future Mayor: In The Fight Against Opioids, Be Bold
We Can Understand Why The Prospect of an Overdose Prevention Site, Also Known as a Supervised or Safe Injection Site, Gives Some Elected Officials Pause. But Hear Us Out.
Patients With Opioid Addiction Describe the Factors That Make Them Quit Methadone
Q&A With Dr. Ashish Thakrar Reveals Policy Gaps and How the System Could Be Improved
Vending Machines Are Dispensing Hope and Health in Philadelphia’s Opioid Crisis
They Deliver Drugs and Tools to Fight the Epidemic; Community Members Suggest Strategies for How They Can Gain Acceptance